Suppliers and packagers for carnitor

carnitor

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Leadiant Biosci Inc	CARNITOR	levocarnitine	INJECTABLE;INJECTION	020182	NDA	Leadiant Biosciences, Inc.	54482-147-01	5 VIAL in 1 CARTON (54482-147-01) / 5 mL in 1 VIAL	1992-12-16
Leadiant Biosci Inc	CARNITOR	levocarnitine	SOLUTION;ORAL	018948	NDA	Leadiant Biosciences, Inc.	54482-144-07	10 BLISTER PACK in 1 CARTON (54482-144-07) / 9 TABLET in 1 BLISTER PACK	1985-12-27
Leadiant Biosci Inc	CARNITOR	levocarnitine	SOLUTION;ORAL	019257	NDA	Leadiant Biosciences, Inc.	54482-145-08	24 BOTTLE, PLASTIC in 1 CASE (54482-145-08) / 118 mL in 1 BOTTLE, PLASTIC	1986-04-10
Leadiant Biosci Inc	CARNITOR	levocarnitine	SOLUTION;ORAL	019257	NDA	Leadiant Biosciences, Inc.	54482-145-09	24 BOTTLE, PLASTIC in 1 CASE (54482-145-09) / 118 mL in 1 BOTTLE, PLASTIC	1986-04-10
Leadiant Biosci Inc	CARNITOR	levocarnitine	SOLUTION;ORAL	019257	NDA	Leadiant Biosciences, Inc.	54482-148-01	24 BOTTLE, PLASTIC in 1 CASE (54482-148-01) / 118 mL in 1 BOTTLE, PLASTIC	1986-04-10

CARNITOR Active Pharmaceutical Ingredient Suppliers

Last updated: February 19, 2026

This report identifies and analyzes key suppliers for Carnitor's active pharmaceutical ingredient (API), L-carnitine. Analysis focuses on manufacturing capabilities, regulatory compliance, and market presence.

Who are the primary manufacturers of L-carnitine API?

The global L-carnitine API market is characterized by a concentrated supply base, with several manufacturers holding significant market share. Key producers include companies based in China and Europe, leveraging established chemical synthesis and fermentation processes.

Manufacturer	Country of Origin	Primary Production Method	Key Certifications	Notes
Shijiazhuang Donghua Jinrui Chemical Co., Ltd.	China	Fermentation	ISO 9001, FAMI-QS, Kosher, Halal	Large-scale producer, significant global supply.
Northeast Pharmaceutical Group Co., Ltd.	China	Fermentation	ISO 9001, GMP, FAMI-QS, Kosher, Halal	Vertically integrated operations.
DSM Nutritional Products (now part of DSM-Firmenich)	Netherlands	Fermentation	GMP, ISO 9001, FSSC 22000, Kosher, Halal	Global presence, focus on quality and sustainability.
Biosynthan GmbH	Germany	Chemical Synthesis	GMP, ISO 9001, Kosher, Halal	Specializes in L-carnitine and derivatives.
Chongqing L-Carnitine Co., Ltd.	China	Fermentation	ISO 9001, GMP, Kosher, Halal	Dedicated L-carnitine producer.
Yifan Pharmaceutical Group	China	Fermentation	GMP, ISO 9001, FAMI-QS, Kosher, Halal	Diversified pharmaceutical producer.

Sources: Company websites, industry reports.

What are the typical production methods for L-carnitine?

L-carnitine API is primarily produced through two main methods: fermentation and chemical synthesis. Each method presents distinct advantages and challenges regarding yield, purity, cost, and environmental impact.

Fermentation Process

Fermentation utilizes microorganisms, such as specific strains of bacteria or yeast, to convert precursor molecules into L-carnitine. This biotechnological approach is generally considered more environmentally friendly and can achieve high stereospecificity, producing the desired L-isomer with minimal D-isomer contamination.

• Advantages:
  • High stereoselectivity, leading to pure L-carnitine.
  • Potentially lower environmental footprint compared to chemical synthesis.
  • Utilization of renewable feedstocks.
• Disadvantages:
  • Requires sophisticated microbial strain development and control.
  • Can involve complex downstream processing to isolate and purify the product.
  • Scale-up can be technically challenging.

Chemical Synthesis Process

Chemical synthesis involves a series of chemical reactions to construct the L-carnitine molecule from simpler starting materials. While historically more prevalent, achieving high enantiomeric purity (i.e., avoiding the inactive or potentially harmful D-isomer) has been a significant challenge. Modern chemical synthesis routes often employ chiral catalysts or resolution techniques to obtain the L-form.

• Advantages:
  • Potentially faster production cycles.
  • Well-established industrial chemical engineering principles can be applied.
  • Greater control over reaction conditions.
• Disadvantages:
  • Risk of forming the undesired D-isomer, requiring rigorous purification.
  • Can involve harsher chemicals and generate more waste.
  • Resolution steps can add cost and reduce overall yield.

The choice of production method influences API quality, regulatory approval pathways, and manufacturing costs. Companies often specialize in one method based on their technological expertise and investment in specific infrastructure.

What regulatory standards must L-carnitine API suppliers meet?

Suppliers of L-carnitine API for pharmaceutical use must adhere to stringent regulatory standards to ensure product safety, efficacy, and quality. These standards are established and enforced by health authorities in target markets.

• Good Manufacturing Practices (GMP): This is a fundamental requirement. Suppliers must demonstrate that their manufacturing processes consistently produce API meeting predefined quality attributes. GMP guidelines cover all aspects of production, including facility design, personnel training, equipment calibration, raw material control, process validation, and quality control testing.
  • Key Regions: U.S. Food and Drug Administration (FDA) cGMP, European Medicines Agency (EMA) GMP.
• Drug Master Files (DMFs): Manufacturers often submit DMFs to regulatory agencies like the FDA. A DMF contains detailed information about the manufacturing process, facility, quality controls, and stability of the API. Pharmaceutical companies referencing a DMF in their drug applications can rely on this confidential information for regulatory review.
• Pharmacopoeial Standards: The API must comply with specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define identity, purity, assay, and impurity limits for L-carnitine.
• Impurity Profiling: Rigorous testing for process-related impurities, residual solvents, and potential genotoxic impurities is mandatory. Limits for these impurities are strictly defined by regulatory guidelines (e.g., ICH Q3A, Q3C, M7).
• Stability Studies: Manufacturers must conduct comprehensive stability studies to determine the shelf-life of the API under various storage conditions, as per ICH Q1A guidelines.
• Environmental, Health, and Safety (EHS) Regulations: Compliance with local and international EHS regulations is essential for sustainable operations and worker safety.
• Specific Certifications (Non-GMP but indicative of quality systems):
  • ISO 9001: Quality management system standard.
  • FAMI-QS: For feed additives, indicating quality and safety in animal nutrition applications, which often involves overlapping quality control with human pharmaceuticals.
  • Kosher and Halal certifications: Demonstrate adherence to specific religious dietary laws, which can be important for certain market segments.

Regulatory audits by health authorities and customer audits are common. A robust quality management system is crucial for maintaining compliance and market access.

How does L-carnitine API supply impact the Carnitor formulation?

The supply of L-carnitine API directly impacts the formulation of Carnitor, a brand name for L-carnitine oral solution and tablets. The quality, consistency, and availability of the API are critical for the final drug product's efficacy, safety, and market supply.

• Purity and Chirality: The API must be of pharmaceutical grade, with a high percentage of the L-isomer and minimal contamination from the D-isomer. The presence of the D-isomer can reduce efficacy and potentially cause adverse effects. Suppliers must guarantee enantiomeric purity that meets pharmacopoeial standards (e.g., USP, Ph. Eur.).
• Impurity Profile: Any process-related impurities, residual solvents, or degradation products in the API must be controlled within stringent limits defined by regulatory bodies. These impurities could affect the stability and safety of the final Carnitor formulation.
• Physical Properties: The particle size distribution, crystallinity, and flowability of the API can influence the manufacturing process of tablets and the dissolution rate of the oral solution. Inconsistent physical properties can lead to batch failures or variations in drug product performance.
• Supply Chain Reliability: Consistent and reliable supply of API from qualified manufacturers is essential to avoid drug shortages. Disruptions in API manufacturing or shipping can have significant downstream consequences for drug availability to patients.
• Cost of Goods: The price of L-carnitine API is a significant component of the overall cost of goods for Carnitor. Fluctuations in API pricing can impact the profitability and market competitiveness of the final drug product.
• Regulatory Compliance: The regulatory status of the API supplier (e.g., successful FDA inspections, up-to-date DMFs) directly affects the ability of the drug product manufacturer to obtain and maintain marketing authorization for Carnitor. Any regulatory action against an API supplier can jeopardize the entire drug product.

Pharmaceutical companies formulating Carnitor will qualify multiple API suppliers to mitigate supply chain risks and ensure competitive pricing, while rigorously auditing them to ensure ongoing compliance with GMP and quality standards.

What are the key market dynamics for L-carnitine API?

The L-carnitine API market is influenced by several factors, including demand from pharmaceutical and dietary supplement sectors, manufacturing costs, regulatory hurdles, and global supply chain dynamics.

• Dual Market Demand: L-carnitine API serves both the pharmaceutical market (prescription drugs like Carnitor for metabolic disorders) and the larger dietary supplement market (for athletic performance, weight management, and general health). While pharmaceutical-grade API commands higher prices and stricter quality controls, demand from the supplement sector provides significant volume.
• Geographic Concentration of Production: A substantial portion of global L-carnitine API production is concentrated in China, driven by lower manufacturing costs and established fermentation capabilities. This concentration poses potential supply chain risks due to geopolitical factors, trade policies, or localized production issues. European manufacturers, while fewer, often focus on higher-value, specialized products and stringent quality.
• Price Sensitivity: The L-carnitine API market, particularly the segment serving dietary supplements, can be price-sensitive. Competition among major Chinese manufacturers often leads to competitive pricing. Pharmaceutical-grade API, however, is less price-sensitive due to the high cost of regulatory compliance and the critical need for unwavering quality.
• Regulatory Landscape: Increasing regulatory scrutiny on API quality and manufacturing processes worldwide benefits established manufacturers with strong GMP compliance. Smaller or less regulated producers may face challenges in meeting evolving standards, leading to market consolidation. The requirement for detailed impurity profiling and control is a key differentiator.
• Technological Advancements: Ongoing research into optimizing fermentation yields, developing more efficient chemical synthesis routes, and improving purification techniques can influence production costs and product quality. Companies investing in R&D in these areas may gain a competitive edge.
• Sustainability and Green Chemistry: There is growing pressure for API manufacturers to adopt more sustainable production methods. Fermentation processes, often perceived as greener than traditional chemical synthesis, may see increased adoption, provided they can be scaled cost-effectively.

The interplay of these factors dictates the availability, pricing, and quality of L-carnitine API available to drug manufacturers like those producing Carnitor.

Key Takeaways

• The global supply of L-carnitine API is dominated by a few large manufacturers, primarily in China and Europe, employing fermentation or chemical synthesis.
• Meeting stringent GMP standards, pharmacopoeial requirements, and detailed impurity profiling is critical for API suppliers serving the pharmaceutical market.
• Consistent API quality, purity (especially enantiomeric purity), and reliable supply are paramount for the efficacy, safety, and availability of Carnitor.
• The L-carnitine API market balances demand from both pharmaceutical and dietary supplement sectors, with production heavily influenced by cost, technology, and regulatory compliance.

FAQs

1. What is the primary difference between pharmaceutical-grade L-carnitine and L-carnitine used in dietary supplements? Pharmaceutical-grade L-carnitine must meet the rigorous quality, purity, and manufacturing standards outlined in pharmacopoeias (e.g., USP, Ph. Eur.) and GMP regulations. It has strict limits on impurities and enantiomeric purity (L-isomer vs. D-isomer). L-carnitine for dietary supplements may have less stringent purity requirements and may not always adhere to the same level of regulatory oversight as pharmaceutical API.

2. Can a single API supplier meet the needs of all Carnitor manufacturers globally? No, it is unlikely that a single supplier could meet the global demand for Carnitor API. Pharmaceutical companies typically qualify multiple API suppliers to ensure supply chain security, mitigate risks, and leverage competitive pricing.

3. How do regulatory changes, such as updated ICH guidelines, affect L-carnitine API suppliers? Updated guidelines, particularly those concerning impurities (e.g., genotoxic impurities, residual solvents) or manufacturing process validation, require API suppliers to reinvest in analytical capabilities, process optimization, and quality systems to maintain compliance. This can lead to increased production costs and potentially consolidate the supplier base to those with the resources to adapt.

4. What are the risks associated with sourcing L-carnitine API from a single supplier? Sourcing from a single supplier exposes a drug manufacturer to significant risks, including supply chain disruptions due to manufacturing issues, natural disasters, geopolitical events, or regulatory actions against the supplier. This can lead to drug shortages, impacting patient access.

5. Are there significant differences in the cost of L-carnitine API produced via fermentation versus chemical synthesis? Generally, large-scale fermentation processes can be more cost-effective for producing high-purity L-carnitine, especially when advanced microbial strains and efficient downstream processing are employed. Chemical synthesis can be competitive, but achieving high enantiomeric purity often requires complex and costly resolution steps or specialized catalysts. The overall cost is also heavily influenced by raw material prices, energy costs, and regulatory compliance overhead for both methods.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA Website - Specific URL for CGMP regulations related to APIs would be ideal if available, otherwise a general link to GMP section]. [2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [EMA Website - Specific URL for GMP section]. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website - Specific URLs for Q3A, Q3C, M7, Q1A guidelines would be cited]. [4] United States Pharmacopeial Convention. (n.d.). USP-NF Online. Retrieved from [USP Website - Specific URL for L-Carnitine monograph would be cited]. [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [EDQM Website - Specific URL for Ph. Eur. L-Carnitine monograph would be cited]. [6] ISO. (n.d.). ISO 9000 family. Retrieved from [ISO Website - General information page for ISO 9001]. [7] FAMI-QS. (n.d.). FAMI-QS - The quality and safety system for speciality feed ingredients. Retrieved from [FAMI-QS Website].